Showing results (1-10 of 368) with videos related to
Sort By:
Pageof 37
JAMA Network Open|May 11, 2019
Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled AnalysisAlfredo Addeo, Glen J Weiss, Bishal GyawaliRecenti Progressi in Medicina|May 12, 2017
Biosimilars in oncology: everybody agrees but nobody uses?Bishal GyawaliJournal of the National Cancer Institute|November 8, 2025
De-escalation trials do not always need to be non-inferiority- A case for superiority design de-escalation trials in oncologyBishal GyawaliEcancermedicalscience|April 8, 2017
Low-value practices in oncology contributing to financial toxicityBishal GyawaliEcancermedicalscience|May 11, 2018
Cancer treatment in the last 6 months of life: when inaction can outperform actionBishal Gyawali, Saroj NiraulaAMA Journal of Ethics|February 13, 2020
When Is a Suboptimal Approach to Cancer Screening Better Than None?Ramy Sedhom, Bishal GyawaliCancer Treatment Reviews|September 2, 2017
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trialsBishal Gyawali, Saroj NiraulaNature Reviews. Clinical Oncology|November 29, 2017
Me too-drugs with limited benefits - the tale of regorafenib for HCCBishal Gyawali, Vinay PrasadHealthcarepapers|January 24, 2023
Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?Kristina Jenei, Bishal GyawaliPageof 37